KDR and glioblastoma: Among them, the VEGFR2-targeted monobody CT-322 has been tested in phase 2 clinical trials [32], but showed poor efficacy in recurrent glioblastoma possibly due to a lack of clinical effect from inhibiting VEGFR2 [33].